Cart is empty A clinical trial led by Yuejin Yang of the Chinese Academy of Medical Sciences and Peking Union Medical College, China, has concluded that a Chinese traditional medicine compound, Tongxinluo, reduced major adverse cardiac and cerebrovascular events and reduced cardiac deaths.
Leave A Comment